Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMUNOR therapy in children with recurrent respiratory tract infections
2013-001958-10Phase 3Terminated
- Sponsor
- Imunomedica
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in recurrent respiratory tract infection (RRTI) comparing IMUNOR with Placebo (2 arms). Primary endpoint: Number of documented respiratory tract infections during 3 months of treatment. Started May 2013; status: terminated.
02
Drugs
inosine pranobex
03
Conditions
recurrent respiratory tract infection (RRTI)
Beyond the preview
Go deeper on 2013-001958-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001958-10.